Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Annovis Bio, Inc.

NYSE: ANVS · Life Sciences · 7 alerts · CIK 1477845

Share price
$0.7500Close, Nov 16
Market cap
$46.5M
Shares outstanding
62.02MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Annovis Bio, Inc. filings on SEC EDGAR ↗

4:33 PM ET 10-Q
Financial Results

Annovis Bio Q3 2026 Results: Net Loss of $9.46M, Loss Widens

Annovis Bio reported a net loss of $41.9 million for the nine months ended September 30, 2026, compared to $19.0 million in the prior year, driven primarily by a significant increase in research and development expenses. The company's cash position decreased to $2.8 million from $19.5 million at the end of 2025, though it raised approximately $30.2 million through equity and warrant issuances during the period.

Key figure
Net loss $9.46M
4:24 PM ET 8-K
Financial Results

Annovis Bio Financial Results

Annovis Bio reported third quarter 2026 financial results and provided a clinical update on its Phase 3 DUET-AD study for Alzheimer's disease, with a data readout expected in March 2027. The company also highlighted a $21.0 million capital raise from an underwritten public offering intended to fund operations through the upcoming clinical milestones.

Term
Q3 2026

“The third quarter marked a shift in our focus from enrolling patients in DUET-AD to executing the trial and preparing for the first data readout and for filing a New Drug Application (NDA). We now have dates set for last patient, last visit of the 6-month treatment period and for database lock, as well as financing in place to carry us through topline results in March 2027. The team is working very hard to deliver clean data and an on-time readout.”

Maria Maccecchini, PhD, President and CEO of Annovis
4:30 PM ET Form 4
Insider Buying

Annovis Bio Insider Michael B. Hoffman Buys $5M of Stock

Michael B. Hoffman bought 5,000,000 shares of Annovis Bio, Inc. at $1.00 a share, worth $5M in total on Nov 6, 2026. Shares held after the trade: 8,364,883 (+148.6%).

Value
$5M
Shares
5,000,000
Price
$1.00
Holding change
+148.6%
Trade date
Nov 6, 2026
5:25 PM ET 8-K
Capital Raise

Annovis Bio Capital Raise of $21M

Annovis Bio entered into an underwriting agreement to raise approximately $21.0 million through a public offering of 19,000,000 shares of common stock and 2,000,000 pre-funded warrants, accompanied by warrants to purchase an additional 21,000,000 shares. The company intends to use the proceeds for the clinical development of its lead compound, Buntanetap, in studies for Alzheimer’s and Parkinson’s disease.

Value
$21M
Counterparty
Canaccord Genuity LLC
4:08 PM ET 8-K
Business Update

Annovis Bio Business Update

Annovis Bio provided a preliminary estimate of its cash and cash equivalents, which were approximately $2.8 million as of September 30, 2026. The company noted that it has not yet completed its quarterly financial closing processes and the figure is subject to change upon completion of its full interim financial statements.

4:06 PM ET 8-K
Stock Plan Amendment

Annovis Bio Stock Plan Amendment

Annovis Bio stockholders approved an amendment to the 2019 Equity Incentive Plan to increase the number of authorized shares available for issuance. Additionally, stockholders approved a charter amendment to double the company's total authorized common stock from 70 million to 140 million shares.

5:11 PM ET 8-K
Nasdaq/NYSE Compliance Notice

Annovis Bio Nasdaq/NYSE Compliance Notice

Annovis Bio received a deficiency notice from the NYSE for failing to maintain a minimum average market capitalization of $50 million and stockholders' equity of $50 million over a 30-day period. The company has 45 days to submit a compliance plan and 9 months to regain compliance to avoid delisting. During this period, the stock will continue to trade under the symbol 'ANVS' with an added '.BC' designation.

Counterparty
NYSE
Term
9 months

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.